Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma

Background & AimsIn the US, inequal liver transplantation (LT) access exists between patients with and without hepatocellular carcinoma (HCC). Survival benefit considers survival LT could equalize access. We calculated bias-corrected for transplanted with(out) HCC, based on longitudinal data in a recent US cohort.Methods ResultsAdult candidates HCC 2010-2019 were included. Waitlist over time was contrasted to posttransplant survival, estimate 5-year from moment of LT. modeled Cox regression estimated through proportional hazards regression. Mean always lower than non-HCC waitlist survival. Below MELD(-Na) 30, gained more life-years at same score. Only below 9 had negative benefit. Most 14 most above 26. Liver function (MELD(-Na), albumin) main predictor Therefore, during five years, 0.12 1.96 years LT, whereas 2.48 3.45 years.ConclusionsOn an individual level, transplanting resulted However, population indirectly decreased, as likely gain due decreased function. For patients, constructed online calculator estimates given specific patient characteristics. scores serve access.Lay summary- Benefit is comparison it important when deciding who should be transplanted.- predicting possible transplantation.- Patients cancer die sooner waiting list compared similar cancer. often have better function.- derive